Calico Life Sciences, LLC
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Calico Life Sciences, LLC
A Tale Of Two Gene Therapy Biotechs: Freeline Divests As Kriya Invests
Freeline Therapeutics and Kriya are taking divergent paths to success amid market doldrums, as the former divests and pulls back on investment, while the latter bulks up its pipeline through an acquisition.
Deal Watch: Aging-Focused Calico Taps Start-Up Terray For Discovery
Terray/Calico tie-up will focus on small molecule discovery for diseases of aging, including cancer. Lilly, AstraZeneca sign discovery pacts with Nimbus and Illumina, respectively.
Hal Barron To Depart GSK To Head Up New Biotech
As Barron departs for new rejuvenation-focused biotech Altos Labs, GSK will be under pressure to ensure its R&D can continue to produce green shoots.
Deal Watch: Seagen Ups Presence In HER2-Positive Cancer Field With RemeGen Deal
Lilly partners with Kumquat to discover small molecule IO drug. Kite, Appia Bio collaborate on allogeneic cell therapies. AstraZeneca and Regeneron pursue novel metabolic therapies targeting GPR75. Lexeo and Stelios merge to focus on gene therapies for rare cardiovascular indications.
- Drug Discovery Tools
- Other Names / Subsidiaries
- Calico Group LLC
- Calico LLC
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.